Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2010
06/03/2010WO2010061282A1 Derivatives of [(3-hydroxy-4 pyron-2-yl)methyl]-amine and use thereof as anti-neoplastic drugs
06/03/2010WO2010061246A1 Use of p2x7 pathway for assessing the sensitivity of a subject to a cancer treatment
06/03/2010WO2010061220A2 Novel processes and pure polymorphs
06/03/2010WO2010061219A2 Polymorphs
06/03/2010WO2010061210A1 Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
06/03/2010WO2010061208A2 Therapeutic treatment 555
06/03/2010WO2010061185A2 Therapeutic target
06/03/2010WO2010061180A1 Quinoline derivatives as p13 kinase inhibitors
06/03/2010WO2010061142A2 Composition for slowing cancer cell tumor initiation in a high-risk mammal
06/03/2010WO2010061088A1 Pharmaceutical association lipoic acid and hydroxycitric acid as active ingredients
06/03/2010WO2010061074A1 Indole derivatives, method for preparing same and pharmaceutical compositions containing same
06/03/2010WO2010061018A1 Use of n-acetylcystin for protecting fish against microcystin poisoning
06/03/2010WO2010061005A1 Method to produce hyaluronic acid functionalized derivatives and formation of hydrogels thereof
06/03/2010WO2010061000A1 Novel porcine circovirus type 2b isolate and uses thereof
06/03/2010WO2010060990A1 Use of p2x7 pathway for assessing the sensitivity of a subject to a cancer treatment
06/03/2010WO2010060968A1 Regioselective reduction of fused pyrrolocarbazoles-5,7-diones
06/03/2010WO2010060967A2 Compositions and methods for treating retrovirus infections
06/03/2010WO2010060958A1 Controlled release pharmaceutical compositions comprising o-desmethyl-venlafaxine
06/03/2010WO2010060955A1 Novel 2-morpholino-3-amido-pyridine derivatives and their medical use
06/03/2010WO2010060952A1 6,7,8,9-tetrahydro-5h-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
06/03/2010WO2010060941A2 Contrast agents
06/03/2010WO2010060940A2 Hsp90 inhibitors for therapeutic treatment
06/03/2010WO2010060937A2 Hsp90 inhibitor combinations
06/03/2010WO2010060904A1 Bicyclic peptidomimetic inhibitors of aspartyl-proteases for the treatment of infectious diseases
06/03/2010WO2010060891A1 Rocaglaol derivatives as cardioprotectant agents and as antineoplastic agents
06/03/2010WO2010060886A2 Mouthwash in the form of a stable suspension comprising microspheres that incorporate an active ingredient
06/03/2010WO2010060875A1 Novel powdered crystalline medicines for inhalation
06/03/2010WO2010060874A1 Phosphodiesterase type iii (pde iii) inhibitors or ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
06/03/2010WO2010060854A1 Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
06/03/2010WO2010060852A1 Novel piperidine-butyramide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
06/03/2010WO2010060836A1 Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists
06/03/2010WO2010060798A1 Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester
06/03/2010WO2010060742A1 Combination of bifeprunox and an antipsychotic drug with d2/5-ht2a receptor antagonistic activity for treating cns disorders
06/03/2010WO2010060729A1 Therapeutic, dietary, or cosmetic use of compounds with specific anti-apoptotic activity toward caspase-3, and compositions containing these compounds
06/03/2010WO2010060703A1 3-(benzylamino)-pyrrolidine derivatives and their use as nk-3 receptor antagonists
06/03/2010WO2010060644A1 Use of carboxymethylcellulose to control ejectability and solidification of time of compositions one or more bioresorbable ceramics
06/03/2010WO2010060635A2 Solid pharmaceutical composition comprising at least one stabilizing agent
06/03/2010WO2010060624A2 Dry processing and novel forms of lacosamide
06/03/2010WO2010060589A1 Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
06/03/2010WO2010060564A1 Pharmaceutical dosage form comprising nifedipine or nisoldipine and an angiotensin-ii antagonist and/or a diuretic
06/03/2010WO2010060532A1 Benzonaphtyridine compounds used as inhibitors of autotaxin
06/03/2010WO2010060529A1 Microparticles comprising a salt of 8-hydroxy-2- [ [ ( ir) -2- (4-methoxyphenyl) -l-methylethyl] aminol ethyll -2 (ih) -quinolin one
06/03/2010WO2010060522A2 Difluorphenyl diacylhydrazide derivates
06/03/2010WO2010060472A1 Imidazopyridazine derivatives acting as orexin antagonists
06/03/2010WO2010060471A1 Piperidine derivatives useful as orexin receptor antagonists
06/03/2010WO2010060470A1 Piperidine derivatives useful as orexin receptor antagonists
06/03/2010WO2010060387A1 The five crystal forms of the nicousamide, the preparation methods, the pharmaceutical compositions and the uses thereof
06/03/2010WO2010060277A1 Substituted acetyl hydrazide derivatives, their preparation and uses thereof
06/03/2010WO2010060215A1 2-(n-substituted piperazinyl) steroid derivatives
06/03/2010WO2010060214A1 Hybrid -ionone and curcumin molecules as anticancer agents
06/03/2010WO2010060199A1 Transdermally administered aliskiren
06/03/2010WO2010060186A1 Antibodies that specifically block the biological activity of a tumor antigen
06/03/2010WO2010060171A1 Moisturizing mixture, cosmetic and/or pharmaceutical compositions containing the moisturizing mixture, use of the moisturizing mixture, and cosmetic method
06/03/2010WO2010042392A3 Hiv integrase inhibitors
06/03/2010WO2010042391A3 Hiv integrase inhibitors
06/03/2010WO2010041242A3 Oxidized thiophospholipid compounds and uses thereof
06/03/2010WO2010041017A3 Chewable gelled emulsions
06/03/2010WO2010040803A3 Kv1.3 channel blocking substances for the treatment of diseases associated with intimal hyperplasia
06/03/2010WO2010038240A9 Pharmaceutical composition comprising nimesulide and levocetirizine
06/03/2010WO2010037785A3 Inhibitors of f18+ e coli binding
06/03/2010WO2010036773A8 Deuterated 1-aryl-2 -aminomethyl cyclopropane carboxyamide derivatives
06/03/2010WO2010036395A3 Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
06/03/2010WO2010033647A3 Cysteine labeling system and method of use thereof
06/03/2010WO2010033560A3 Sur1 inhibitors for therapy
06/03/2010WO2010033247A3 Reduced size self-delivering rnai compounds
06/03/2010WO2010032147A3 Hydroxamic acid derivatives useful as antibacterial agents
06/03/2010WO2010030891A3 Aryl guanidine f1f0-atpase inhibitors and related methods
06/03/2010WO2010030598A3 Pharmaceutical formulations comprising pemetrexed
06/03/2010WO2010028213A3 N-sulfonamido polycyclic pyrazolyl compounds
06/03/2010WO2010027498A3 Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions
06/03/2010WO2010027424A3 9-substituted phenanthrene based tylophorine derivatives
06/03/2010WO2010026545A9 Manganese and cobalt complexes, their preparation and use
06/03/2010WO2010023690A3 Prolonged release formulation of amisulpride
06/03/2010WO2010022277A3 Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers
06/03/2010WO2010021607A3 Pharmaceutical formulation
06/03/2010WO2010020920A3 Anti-parkinsonian compound acetylsalicylic acid maltol ester
06/03/2010WO2010020856A3 Rate modulated delivery of drugs from a composite delivery system
06/03/2010WO2010019276A3 Method and formulation for treating adverse biological conditions
06/03/2010WO2010016681A3 Pharmaceutical composition containing 1,2-dithiolthione derivative for preventing or treating disease caused by overexpression of lxr-alpha
06/03/2010WO2010015657A3 Alkoxypyrazoles and the process for their preparation
06/03/2010WO2010015656A3 Alkoxypyrazoles and the process for their preparation
06/03/2010WO2010014257A3 Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
06/03/2010WO2010013975A3 A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivative or its salt, and bisphosphonate
06/03/2010WO2010012811A3 Method for screening of 5ht7 receptor ligands based on a new pharmacophore model and a descriptor's profile filter
06/03/2010WO2010009210A3 Acetylsalicyclic acid derivatives useful to treat metabolic syndromes
06/03/2010WO2010009056A3 Pain relieving patch
06/03/2010WO2009150405A8 Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine
06/03/2010WO2009121935A3 Pharmaceutical composition with bisphosphonate
06/03/2010WO2009109654A8 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
06/03/2010WO2009074020A9 Alpha-amino-n-substituted amides, pharmaceutical composition containing them and uses thereof
06/03/2010WO2009067856A8 Histone deacetylase inhibitor, composition and use thereof
06/03/2010WO2009061652A8 Compounds which modulate the cb2 receptor
06/03/2010WO2009053715A8 Thienopyrimidiene derivatives as pi3k inhibitors
06/03/2010WO2009052090A8 Silicate containing compositions and methods of treatment
06/03/2010WO2008151303A8 Long wavelength fluorogenic intercellular ion indicators
06/03/2010WO2008131348A3 Compositions and methods for treatment of uncontrolled cell growth
06/03/2010WO2008115694A3 Polymerization of multifunctional azides, and polymers therefrom
06/03/2010US20100138957 Hybrid peptides having antimicrobial activity and methods of making and using hybrid peptides
06/03/2010US20100138939 Pig model for atherosclerosis
06/03/2010US20100137976 Systems and Methods for Treating Heart Tissue Via Localized Delivery of Parp Inhibitors
1 ... 2238 2239 2240 2241 2242 2243 2244 2245 2246 2247 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 ... 7860